|
|
|
| Research progress of exosomes and chemotherapeutic resistance in gastrointestinal tumors |
| NI Xiufan1 ZHANG Youli2 XU Min2 |
1.Medical College, Jiangsu University, Jiangsu Province, Zhenjiang 212000, China;
2.Department of Gastroenterology, Affiliated Hospital of Jiangsu University, Jiangsu Province, Zhenjiang 212000, China |
|
|
|
Abstract The digestive system tumor including esophageal cancer, gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, which have high morbidity and mortality. At present, chemotherapy is one of the treatments for digestive system tumors, but long-term application of chemotherapy drugs often causes drug resistance in tumor cells, which is one of the important challenge in tumor treatment. Exosomes are small vesicles with a diameter of 30-100 nm, which are composed of bilayer membrane. The exosomes contain proteins, nucleic acids, lipids, etc. In recent years, it has been found that exosomes participate in a series of tumor development and development by mediating intercellular communication and regulating tumor microenvironment, especially having an important impact on tumor chemotherapy resistance. This paper mainly summarized the domestic and foreign studies on the involvement of exosomes in the chemotherapy resistance of digestive system tumors, aiming to intuitively expound the mechanism of exosomes mediating the chemotherapy resistance of digestive system tumors, and provide new ideas for the study of tumor resistance.
|
|
|
|
|
|
[1] Torre LA，Bray F，Siegel RL，et al. Global cancerstatistics，2012 [J]. CA Cancer J Clin，2015，65（2）：87-108.
[2] Kalluri R. The biology and function of exosomes in cancer [J].J Clin Invest，2016，126（4）：1208-1215.
[3] Raposo G，Stoorvogel W. Extracellular vesicles：exosomes，microvesicles，and friends [J]. J Cell Biol，2013，200（4）：373-383.
[4] Wang X，Luo G，Zhang K，et al. Hypoxic tumor-derived exosomal miR-301a mediates M2 macrophage polarization via PTEN/PI3Kγ to promote pancreatic cancer metastasis [J]. Cancer Res，2018，78（16）：4586-4598.
[5] Chiba M，Watanabe N，Watanabe M，et al. Exosomes derived from SW480 colorectal cancer cells promote cell migration in HepG2 hepatocellular cancer cells via the mitogen-activated protein kinase pathway [J]. Int J Oncol，2016，48（1）：305-312.
[6] Zhang Y，Liu J，Zhang W，et al. Treatment of esophageal cancer with radiation therapy-a pan-Chinese survey of radiation oncologists [J]. Oncotarget，2017，8（21）：34946-34953.
[7] Kang M，Ren M，Li Y，et al. Exosome-mediated transfer of lncRNA PART1 induces gefitinib resistance in esophageal squamous cell carcinoma via functioning as a competing endogenous RNA [J]. J Exp Clin Cancer Res，2018，37（1）：171.
[8] Yang YC，Liu GJ，Yuan DF，et al. Influence of exosome-derived miR-21 on chemotherapy resistance of esophageal cancer [J]. Eur Rev Med Pharmacol Sci，2019，23（4）：1513-1519.
[9] Li TT，Liu H，Yu J，et al. Prognostic and predictive blood biomarkers in gastric cancer and the potential application of circulating tumor cells [J]. World J Gastroenterol，2018， 24（21）：2236-2246.
[10] Liu X，Lu Y，Xu YC，et al. Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer [J]. Cancer Lett，2019， 459：122-134.
[11] Wang J，Lv B，Su Y，et al. Exosome-Mediated Transfer of lncRNA HOTTIP Promotes Cisplatin Resistance in Gastric Cancer Cells by Regulating HMGA1/miR-218 Axis [J]. Onco Targets Ther，2019，12：11325-11338.
[12] Zheng P，Chen L，Yuan X，et al. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells [J]. J Exp Clin Cancer Res，2017，36（1）：53.
[13] Ji RB，Zhang B，Zhang X，et al. Exosomes derived from human mesenchymal stem cells confer drug resistance in gastric cancer [J]. Cell Cycle，2015，14（15）：2473-2483.
[14] Fu X，Liu M，Qu S，et al. Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway [J]. J Exp Clin Cancer Res，2018，37（1）：52.
[15] Lou G，Song X，Yang F，et al. Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma [J]. J Hematol Oncol，2015，8：122.
[16] Takahashi K，Yan IK，Wood J，et al. Involvement of Extracellular Vesicle Long Noncoding RNA（linc-VLDLR）in Tumor Cell Responses to Chemotherapy [J]. Mol Cancer Res，2014，12（10）：1377-1387.
[17] Takahashi K，Yan IK，Kogure T，et al. Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer [J]. FEBS Open Bio，2014，4：458-467.
[18] Ferlay J，Soerjomataram I，Dikshit R，et al. Cancer incidence and mortality worldwide：sources，methods and major patterns in GLOBOCAN 2012 [J]. Int J Cancer，2015， 136（5）：E359-E386.
[19] Wang X，Zhang H，Yang H，et al. Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer [J]. Mol Oncol，2020，14（3）：539-555.
[20] Hu JL，Wang W，Lan XL，et al. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer [J]. Mol Cancer，2019，18（1）：91.
[21] Hu YB，Yan C，Mu L，et al. Exosomal Wnt-induced dedifferentiation of colorectal cancer cells contributes to chemotherapy resistance [J]. Oncogene，2019，38（11）：1951-1965.
[22] Ryan DP，Hong TS，Bardeesy N. Pancreatic adenocarcinoma [J]. N Engl J Med，2014，371（22）：2140-2141.
[23] Mikamori M，Yamada D，Eguchi H，et al. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma [J]. Sci Rep，2017，7：42339.
[24] Yang Z，Zhao N，Cui J，et al. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210 [J]. Cell Oncol（Dordr），2020，43（1）：123-136.
[25] Binenbaum Y，Fridman E，Yaari Z，et al. Transfer of miRNA in macrophages-derived exosomes induces drug resistance of pancreatic adenocarcinoma [J]. Cancer Res，2018，78（18）：5287-5299.
[26] Kamerkar S，Lebleu VS，Sugimoto H，et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer [J]. Nature，2017，546（7659）：498-503.
[27] Ha D，Yang N，Nadithe V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes：current perspectives and future challenges [J]. Acta Pharm Sin B，2016，6（4）：287-296.
[28] Aung T，Chapuy B，Vogel D，et al. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3 [J]. Proc Natl Acad Sci U S A，2011，108（37）：15336-15341.
[29] Zhang J，Zhang HD，Yao YF，et al. β-Elemene Reverses Chemoresistance of Breast Cancer Cells by Reducing Resistance Transmission via Exosomes [J]. Cell Physiol Biochem，2015，36（6）：2274-2286.
[30] Wang X，Zhang H，Bai M，et al. Exosomes serve as nanoparticles to deliver anti-miR-214 to reverse chemoresistance to cisplatin in gastric cancer [J]. Mol Ther，2018，26（3）：774-783.
[31] Liang G，Zhu Y，Ali DJ，et al. Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer [J]. J Nanobiotechnology，2020，18（1）：10. |
|
|
|
